Eli Lilly follows JNJ in suing govt. over 340B drug-discount program
Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
Lilly Sues US Agency Over Blocking of Drug-Rebate Program
Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...
European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Oil heads for weekly loss as Chinese demand continues to underperform
Oil prices fell on Friday on signs demand in China, the world's biggest crude importer, continues to underperform amid its ...
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...
Smart toilet, AI platform among tech in use at drugmaker Eli Lilly’s new $42m hub in S’pore
The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.
Wolfe sees attractive Eli Lilly opportunity on price drop, starts at Outperform
Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...
Verywell Health on MSN15h
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
Lilly Sues U.S. to Change Hospital Drug Discount Payments
The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
MSCS joins 'mass action' suit against drug companies over insulin costs
Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...